

Ref. No: 007010422
From: Commercial
Date: 01/04/22
Subject: Breast Cancer Treatment

REQUEST

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- Abemaciclib (Verzenios) + aromatase inhibitor *
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
- Alpelisib (Piqray) + Fulvestrant (Faslodex)
- Atezolizumab (Tecentriq)**
- Bevacizumab (Avastin)
- Eribulin (Halaven)
- Everolimus (Afinitor) + Exemestane
- Fulvestrant (Faslodex) as a single agent
- Gemcitabine + paclitaxel
- Herceptin (Trastuzumab) + paclitaxel
- Herceptin (Trastuzumab) as a single agent
- Lapatinib (Tyverb)
- Neratinib (Nerlynx)
- Olaparib (Lynparza)

- Palbociclib (Ibrance) + aromatase inhibitor*
- Palbociclib (Ibrance) + Fulvestrant (Faslodex)
- Pertuzumab (Perjeta) + trastuzumab + docetaxel
- Ribociclib (Kisqali) + aromatase inhibitor*
- Ribociclib (Kisqali) + Fulvestrant (Faslodex)
- Talazoparib (Talzenna)
- Trastuzumab emtansine (Kadcyla)
- Other active systemic anti-cancer therapy **

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

RESPONSE

The Trust is unable to answer this request as we do not record drug names specifically on Somerset.